Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 128, Issue 7, Pages 2691-2701Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI97946
Keywords
-
Categories
Funding
- Ministry of Education, Culture, Sports, Science and Technology (MEXT)/Japan Society for the Promotion of Science KAKENHI [15H04708, 15H05897, 18H02627, 17K082, S29229003]
- AMED GAPFREE Program [17ak0101043h0003]
- Takeda Science Foundation
- Naito Foundation
- Mitsubishi Foundation
- Foundation of Strategic Research Projects in Private Universities from MEXT [S1311011]
- Institute for Environmental and Gender-Specific Medicine
- Shimadzu Co. Ltd., Japan
- ONO Pharmaceutical Co.
- Grants-in-Aid for Scientific Research [15H04708, 18H02627, 15H05897] Funding Source: KAKEN
Ask authors/readers for more resources
Leukotrienes, a class of arachidonic acid-derived bioactive molecules, are known as mediators of allergic and inflammatory reactions and considered to be important drug targets. Although an inhibitor of leukotriene biosynthesis and antagonists of the cysteinyl leukotriene receptor are clinically used for bronchial asthma and allergic rhinitis, these medications were developed before the molecular identification of leukotriene receptors. Numerous studies using cloned leukotriene receptors and genetically engineered mice have unveiled new pathophysiological roles for leukotrienes. This Review covers the recent findings on leukotriene receptors to revisit them as new drug targets.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available